feed,title,long_url,short_url
Benzinga,NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares,https://www.benzinga.com/pressreleases/20/12/g18593592/novelstem-increases-newstem-ownership-to-33-as-newstem-prepares-for-first-half-2021-fda-filing-for,https://j.mp/37o5BZB
